Vall d'Hebron University Hospital

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

Retrieved on: 
Friday, January 19, 2024
Vall d'Hebron University Hospital, Teaching hospital, Borderline personality disorder, Yale school, BPD, Yale School of Medicine, MD, Vall, Genomics, Webcast, Doctor of Philosophy, KOL, Phase

To register for the event, click here .

Key Points: 
  • To register for the event, click here .
  • The event will feature a brief review of the topline results of the Phase IIb PORTICO study, then a discussion with:
    KOL Marc Ferrer, MD, PhD (Vall d'Hebron University Hospital), PORTICO E.U.
  • KOL Sarah Fineberg, MD, PhD (Yale School of Medicine), a Psychiatrist not involved with PORTICO to provide an independent clinician’s perspective on the potential clinical and real-world implications for the results.
  • A replay of the webcast will be available on the company’s website after the event.

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

Retrieved on: 
Friday, December 8, 2023
Trastuzumab, Research, Progression-free survival, RECIST, Fulvestrant, Breast cancer, Jazz Pharmaceuticals, Patient, PFS, Part, Corr, DOR, MBC, DCR, Pertuzumab, HER2, Cancer, Vall d'Hebron University Hospital, BS 5839 Part 1, Metastasis, HR, Pharmaceutical industry, Medical imaging, MD

DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).
  • Patients treated with the combination regimen received a median of four prior systemic regimens in the metastatic setting (range, 1-12).
  • Recommended doses of the zanidatamab plus palbociclib and fulvestrant combination therapy were determined in Part 1 of the study.
  • Patients treated with the combination regimen achieved a cORR of 35% and DCR of 91%.

CARsgen Announces Formation of its Clinical Advisory Board

Retrieved on: 
Monday, November 20, 2023
Dexamethasone, Experiment, Teaching hospital, Patient, Strategic planning, Bortezomib, Vall d'Hebron University Hospital, Cancer, Ernest Beutler, TCO, Doctor of Philosophy, Knowledge, Axicabtagene ciloleucel, University of Miami, Multiple myeloma, Douglas E. Lynch, R.J. Corman Railroad Group, University, ESMO, Harvard Medical School, Regorafenib, Biomarker, Principal, Translation, Vall, MD Anderson Cancer Center, Lenalidomide, Therapy, National Cancer Institute, Dana–Farber Cancer Institute, MGUS, Publication, Drug development, NCI-designated Cancer Center, The Lancet, Research, Lymphoid leukemia, NCI, CD19, MRD, FDA, MD, Survival, Lymphoma, Pharmaceutical industry, Daratumumab, Medicine, Immunotherapy

SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board.

Key Points: 
  • SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formation of its Clinical Advisory Board.
  • This highly regarded panel of experts will provide invaluable guidance and insights for the global clinical development of company's innovative product candidates.
  • "As we embark on this exciting journey to advance our differentiated CAR T-cell therapies, I am delighted to welcome our esteemed Clinical Advisory Board members.
  • The formation of this Clinical Advisory Board marks a significant step forward for CARsgen as it continues to pioneer CAR T-cell therapies with the potential to transform cancer treatment.

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

Retrieved on: 
Monday, October 16, 2023
AXL, Vall d'Hebron University Hospital, NSCLC, Trial of the century, Haukeland University Hospital, Lung cancer, Teaching hospital, OSE, ESMO, Vall, Assistant professor, Nursing, Patient, Poster, Pharmaceutical industry

BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.

Key Points: 
  • BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.
  • Enriqueta Felip, M.D., Ph.D., Head of the Thoracic Cancer Unit at Vall d'Hebron University Hospital, Spain will present the following poster summarizing the final results from the BGBC008 Phase II study of bemcentinib in combination with pembrolizumab in 2L NSCLC:
    Poster Title: Final top-line results of the BGBC008 phase 2, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571) of S
    The poster will be available on BerGenBio's website shortly following presentation.
  • In addition, Dr.  Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical Science at the Haukeland University Hospital in Bergen, Norway will make an oral presentation summarizing the results of the Investigator Led Study LBA52 with bemcentinib in addition to pembrolizumab or dabrafenib/trametinib in 1L and 2L metastatic melanoma patients:
    Martin Olin, Chief Executive Officer of BerGenBio, commented: "We are pleased to share more data on bemcentinib which we believe substantiates our strategy to focus on the treatment of Non-Small Cell Lung Cancer patients with a goal of potentiating the effects of standard of care treatments.
  • We thank the patients who participated in these studies, their families, and all participating investigators as well as their clinical and nursing staff for contributing to our understanding of bemcentinib as a potential cancer therapeutic."

Additional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting

Retrieved on: 
Monday, October 16, 2023
AXL, Vall d'Hebron University Hospital, NSCLC, Trial of the century, Haukeland University Hospital, Lung cancer, Teaching hospital, OSE, ESMO, Vall, Assistant professor, Nursing, Patient, Poster, Pharmaceutical industry

BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.

Key Points: 
  • BERGEN, Norway, Oct. 16, 2023 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid.
  • Enriqueta Felip, M.D., Ph.D., Head of the Thoracic Cancer Unit at Vall d'Hebron University Hospital, Spain will present the following poster summarizing the final results from the BGBC008 Phase II study of bemcentinib in combination with pembrolizumab in 2L NSCLC:
    Poster Title: Final top-line results of the BGBC008 phase 2, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in 2nd line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571) of S
    The poster will be available on BerGenBio's website shortly following presentation.
  • In addition, Dr.  Oddbjorn Straume, M.D., Ph.D., Assistant Professor, Clinical Science at the Haukeland University Hospital in Bergen, Norway will make an oral presentation summarizing the results of the Investigator Led Study LBA52 with bemcentinib in addition to pembrolizumab or dabrafenib/trametinib in 1L and 2L metastatic melanoma patients:
    Martin Olin, Chief Executive Officer of BerGenBio, commented: "We are pleased to share more data on bemcentinib which we believe substantiates our strategy to focus on the treatment of Non-Small Cell Lung Cancer patients with a goal of potentiating the effects of standard of care treatments.
  • We thank the patients who participated in these studies, their families, and all participating investigators as well as their clinical and nursing staff for contributing to our understanding of bemcentinib as a potential cancer therapeutic."

IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial

Retrieved on: 
Friday, June 2, 2023
Pharmaceutical, Health, Oncology, Clinical Trials, Dicarboxylic acid, Docetaxel, Infection, Radiation, IVA, FLOT, Vall d'Hebron University Hospital, Creatinine, Oxaliplatin, Pneumonitis, Adrenocorticotropic hormone, Doctor of Philosophy, AstraZeneca, PCR, Administration, Prednisone, Incidence, MD, Patient, GEJ, Immune system, Cancer, EFS, Warning, ACTH, Stomach, III, Safety, Medical imaging, Pharmaceutical industry, Vaccine, EU

These results demonstrate an increase in pathologic complete response after adding durvalumab treatment to FLOT chemotherapy and surgery.

Key Points: 
  • These results demonstrate an increase in pathologic complete response after adding durvalumab treatment to FLOT chemotherapy and surgery.
  • Immune‑mediated pneumonitis occurred in 1.3% (5/388) of patients receiving IMFINZI and IMJUDO, including fatal (0.3%) and Grade 3 (0.2%) adverse reactions.
  • Immune-mediated colitis occurred in 2% (37/1889) of patients receiving IMFINZI, including Grade 4 (
  • Immune‑mediated colitis or diarrhea occurred in 6% (23/388) of patients receiving IMFINZI and IMJUDO, including Grade 3 (3.6%) adverse reactions.

Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress

Retrieved on: 
Thursday, May 11, 2023
Abstract, RBC, CDL, Pyruvate kinase deficiency, Pharmacy, University, Iron overload, European Hematology Association, Vall d'Hebron University Hospital, Hemolysis, University Medical Center, Effect, Sickle cell disease, Department of Medicine – University of Pamplona, Rated R, Teaching hospital, Harvard Medical School, AGIO, Hematologic disease, Congress, University of Milan, Pyruvate kinase, University Medical Center Utrecht, Translational research, Treatment, University of Verona, CEST, EHA, Utrecht University, Red blood cell, Clinical, Patient, Agios Pharmaceuticals, Rare, Palacký University Olomouc, Myelodysplastic syndrome, Fondazione Child, Dietary supplement, Pharmaceutical industry, Nursing, Doctor of Philosophy, Cancer

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company and its collaborators will present a broad range of clinical and translational data at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Frankfurt, Germany, June 8-11, 2023, and continuing virtually on the Congress platform June 14-15, 2023.

Key Points: 
  • – Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical Benefit of PYRUKYND® (mitapivat) on Hemoglobin, Hemolysis, Iron Overload and Patient-Reported Outcomes –
    CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company and its collaborators will present a broad range of clinical and translational data at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Frankfurt, Germany, June 8-11, 2023, and continuing virtually on the Congress platform June 14-15, 2023.
  • The accepted abstracts are listed below and are available online on the EHA meeting library website.
  • All posters will be presented during the poster session on Friday, June 9 at 16:30-17:45 CEST.
  • All presentations can be accessed on demand by registered meeting attendees on the EHA Virtual Congress platform until Aug. 15, 2023.

New Drug May Help Prevent Migraine for Difficult Cases

Retrieved on: 
Friday, April 21, 2023
DSM-IV codes, Epilepsy, Concussion, Migraine, American Academy of Neurology, Vall d'Hebron University Hospital, Vall, AAN, Stroke, Constipation, CGRP, American Academy, Research, Brain, Multiple sclerosis, Doctor of Philosophy, Teaching hospital, Parkinson's disease, AbbVie, Nervous system, Annual general meeting, Nausea, Headache, Safety, Alzheimer's disease, Social media, Birth control, Dietary supplement, Pharmaceutical industry, MD, Neurology

The study involved people with episodic migraine, which is defined as having up to 14 headache days per month with migraine characteristics.

Key Points: 
  • The study involved people with episodic migraine, which is defined as having up to 14 headache days per month with migraine characteristics.
  • CGRP is a protein that plays a key role in starting the migraine process.
  • The study involved 309 people who had at least four migraine days during the month before the study and who had tried at least two classes of drugs for preventing migraine without improvement.
  • Those taking the drug had an average of four fewer days with migraine per month from the start of the study to the end, while those taking the placebo had about two fewer days with migraine per month.

Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

Retrieved on: 
Wednesday, March 29, 2023
EU, CET, Vall d'Hebron University Hospital, Vall, Hansa, Person, Teaching hospital, Kidney transplantation, EMA, Nephrology, Patient, Nuevos Ministerios, Kidney, Transplant, News, Pharmaceutical industry, Dentistry, Health

The reimbursement approval of Idefirix® in Spain is another important step in this direction, as it now allows highly sensitized patients to be desensitized using Idefirix®, enabling a potentially lifesaving kidney transplant."

Key Points: 
  • The reimbursement approval of Idefirix® in Spain is another important step in this direction, as it now allows highly sensitized patients to be desensitized using Idefirix®, enabling a potentially lifesaving kidney transplant."
  • Of almost 4000 patients registered on the waiting list for a kidney transplant in Spain at the end of 20212, up to one in five (20%)3 are classified as highly sensitized.
  • "Many highly sensitized patients are still disadvantaged and in urgent need of more personalized and innovative desensitization options that can enable incompatible kidney transplantation.
  • This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference

Retrieved on: 
Thursday, March 16, 2023
Conference, Therapy, Division, NETS, Endocrine oncology, Vall d'Hebron University Hospital, ITM, University of Utah, Professor, Gastrointestinal tract, NET, Patient, III, GEP-NET, History, Nuclear medicine, Huntsman Cancer Institute, Biomarker, Doctor of Philosophy, Hospital trust, Associate professor, University, Medical imaging, MD

COMPOSE evaluates the company’s lead radiopharmaceutical candidate, ITM-11 (n.c.a.

Key Points: 
  • COMPOSE evaluates the company’s lead radiopharmaceutical candidate, ITM-11 (n.c.a.
  • 177Lu-edotreotide) compared to standard of care in patients with well-differentiated high grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (G2+G3 SSTR+ GEP-NETs).
  • ITM will also host a hybrid in-person and virtual radiotheranostics satellite symposium titled “Transforming the Therapeutics Landscape for Neuroendocrine Tumors” featuring presentations and discussions between leading endocrine oncology and nuclear medicine clinicians and researchers.
  • ITM will host a medical exhibition booth, as well as a virtual booth during the conference.